Evidence map›Paper›PMID 25777831›Full record

Trial reportInternational journal of stroke : official journal of the International Stroke Society2015

Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.

Jeffrey L Saver, Mayank Goyal, Alain Bonafe, Hans-Christoph Diener, Elad I Levy, Vitor M Pereira, Gregory W Albers, Christophe Cognard, David J Cohen, Werner Hacke and 12 more

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in International journal of stroke : official journal of the International Stroke Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04558125 (Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism), which is not on this map. Cited by 103 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 2 pooled it
32.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04558125 phase4terminatednot on this mapstarted 2020, after this paper: background citation

Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2020 to 2021Enrolled2ConditionsPulmonary Embolism, COVIDArmsTNKase, Placebo, Enoxaparin
3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Isolation and identification of leukocyte populations in intracranial blood collected during mechanical thrombectomy.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Trial
  4. Relative cerebral blood volume is associated with collateral status and infarct growth in stroke patients in SWIFT PRIME.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Improving acute stroke assessment in non-enhanced computed tomography: automated tool for early ischemic lesion volume detection.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Annual Endovascular Thrombectomy Case Volume and Thrombectomy-capable Hospitals of Korea in Acute Stroke Care.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2023
    Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 5 countries.

Jeffrey L SaverDepartment of Neurology and Comprehensive Stroke Center, University of California Los Angeles, Los Angeles, CA, USA.
Mayank Goyal
Alain Bonafe
Hans-Christoph Diener
Elad I Levy
Vitor M Pereira
Gregory W Albers
Christophe Cognard
David J Cohen
Werner Hacke
Olav Jansen
Tudor G Jovin
Heinrich P Mattle
Raul G Nogueira
Adnan H Siddiqui
Dileep R Yavagal
Thomas G Devlin
Demetrius K Lopes
Vivek Reddy
Richard du Mesnil de Rochemont
Reza Jahan
SWIFT PRIME Investigators
University at Buffalo, State University of New York · USUniversity of California, Los Angeles · USUniversity of Pittsburgh Medical Center · USErlanger Health System · USGoethe University Frankfurt · DEGrady Memorial Hospital · USHeidelberg University · DEHôpital Gui de Chauliac · FRKiel University · DERush University Medical Center · USSaint Luke's Hospital · USStanford University · USToronto Western Hospital · CAUniversité de Toulouse · FRUniversity of Bern · CHUniversity of Calgary · CAUniversity of Duisburg-Essen · DEUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleEarly reperfusion in patients experiencing acute ischemic stroke is critical, especially for patients with large vessel occlusion who have poor prognosis without revascularization. Solitaire™ stent retriever devices have been shown to immediately restore vascular perfusion safely, rapidly, and effectively in acute ischemic stroke patients with large vessel occlusions.

aimThe aim of the study was to demonstrate that, among patients with large vessel, anterior circulation occlusion who have received intravenous tissue plasminogen activator, treatment with Solitaire revascularization devices reduces degree of disability 3 months post stroke.

designThe study is a global multicenter, two-arm, prospective, randomized, open, blinded end-point trial comparing functional outcomes in acute ischemic stroke patients who are treated with either intravenous tissue plasminogen activator alone or intravenous tissue plasminogen activator in combination with the Solitaire device. Up to 833 patients will be enrolled. PROCEDURES: Patients who have received intravenous tissue plasminogen activator are randomized to either continue with intravenous tissue plasminogen activator alone or additionally proceed to neurothrombectomy using the Solitaire device within six-hours of symptom onset. STUDY OUTCOMES: The primary end-point is 90-day global disability, assessed with the modified Rankin Scale (mRS). Secondary outcomes include mortality at 90 days, functional independence (mRS ≤ 2) at 90 days, change in National Institutes of Health Stroke Scale at 27 h, reperfusion at 27 h, and thrombolysis in cerebral infarction 2b/3 flow at the end of the procedure. ANALYSIS: Statistical analysis will be conducted using simultaneous success criteria on the overall distribution of modified Rankin Scale (Rankin shift) and proportions of subjects achieving functional independence (mRS 0-2).

Indexed as

StentsAdolescentAdultAgedAged, 80 and overBrain IschemiaFemaleFibrinolytic AgentsFollow-Up StudiesHumansInjections, IntravenousMagnetic Resonance AngiographyMaleMiddle AgedProspective StudiesSeverity of Illness IndexFibrinolytic AgentsTissue Plasminogen Activatoracute ischemic strokeclinical trialendovascularrecanalizationstent retrieverthrombolysis

Identifiers

PMID25777831
PMCPMC4405096
OpenAlexW1505941256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.